Filing and business context
Important identification discrepancy: The request identifies Lisata Therapeutics and 2019 Q3, but the supplied filing is Caladrius Biosciences, Inc.’s Form 10-Q for the quarter ended September 30, 2020, filed November 5, 2020. This summary reflects the supplied filing.
Caladrius is a clinical-stage biopharmaceutical company developing CD34+ cell therapies. Its candidates include HONEDRA for critical limb ischemia, CLBS14 for refractory angina, CLBS16 for coronary microvascular dysfunction, and CLBS119 for COVID-19-related lung damage. The financial statements are unaudited.
Financial results and liquidity
| Metric | Three months ended September 30, 2020 | Nine months ended September 30, 2020 | Comparable 2019 period |
|---|---|---|---|
| Revenue | No revenue line reported | No revenue line reported | No revenue line reported |
| Research and development | $3.0 million | $6.3 million | $3.0 million / $8.0 million |
| General and administrative | $2.3 million | $7.4 million | $2.1 million / $7.0 million |
| Total operating expenses | $5.4 million | $13.7 million | $5.1 million / $15.0 million |
| Net loss | $5.3 million | $2.7 million | $4.9 million / $14.4 million |
| Loss per share, basic and diluted | $0.29 | $0.19 | $0.47 / $1.40 |
The nine-month 2020 net loss includes a $10.9 million income-tax benefit from selling New Jersey net operating losses; before that benefit, loss before tax was $13.6 million. The quarter’s operating loss was $5.35 million; no meaningful operating margin is reported because the statements show no revenue.
For the nine months, operating cash used was $3.3 million, versus $14.7 million in 2019. Investing activities used $8.2 million, principally net purchases of marketable securities; financing provided $18.6 million, primarily from equity and warrant offerings and at-the-market share sales. Cash and cash equivalents were $21.2 million at September 30, 2020, and marketable securities were $19.1 million, for combined liquid resources of $40.3 million. Working capital was $37.1 million.
Total liabilities were $4.5 million, including $0.7 million of operating lease liabilities. The filing reports no borrowing debt. Stockholders’ equity was $37.5 million. Management stated that existing cash was expected to fund operating expenses for at least 12 months after issuance of the financial statements, assuming the CLBS14 Phase 3 trial would require additional dedicated capital.
Changes versus prior comparable periods
- Third-quarter net loss increased to $5.3 million from $4.9 million; operating expenses rose 5%. R&D was broadly unchanged, while G&A increased 12%.
- Nine-month operating expenses declined 9% year over year, mainly as R&D decreased 21%; G&A increased 5%.
- Nine-month reported net loss narrowed substantially from $14.4 million to $2.7 million, primarily due to the $10.9 million tax benefit, not an equivalent improvement in operating performance.
- Combined cash and marketable securities rose from $25.2 million at December 31, 2019 to $40.3 million at September 30, 2020, supported by financing proceeds. Common shares outstanding increased from 10.53 million to 19.41 million during that period.
Outlook, risks, and notable items
- Management expected to complete HONEDRA study enrollment in Japan in the first quarter of 2021; enrollment had been slowed by COVID-19.
- The company expected to initiate a CLBS16 Phase 2b study by the end of 2020. CLBS119’s planned open-label study was designed for 12 patients and had begun screening at NYU Langone Health.
- The CLBS14 confirmatory Phase 3 trial was not to begin until the company secured sufficient capital to fund it through completion. Management estimated approximately $70 million in external trial costs over several years.
- Capital access is a material risk. Management warned that additional financing may be unavailable or dilutive, and that inability to raise funds could delay development plans. The company may also seek partnerships, collaborations, grants, or asset sales.
- COVID-19 could disrupt trials, enrollment, counterparties, and financing. Management said the financial impact could not be reasonably estimated.
- 2020 financing included registered offerings and a private placement involving common shares and immediately exercisable warrants, plus at-the-market sales. These transactions provided capital but diluted existing shareholders and created potential further dilution.
- The CFO resigned effective August 21, 2020. CEO David J. Mazzo was appointed principal financial officer effective November 4, pending appointment of a permanent CFO. The filing reported effective disclosure controls and no material changes in internal control over financial reporting.
- The company reported no material change in legal proceedings and no material pending-claim impact expected. It had a full valuation allowance against deferred tax assets; use of federal NOLs may be limited by ownership-change rules.
Most important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied document is Caladrius Biosciences’ 2020 Q3 filing, not a Lisata Therapeutics 2019 Q3 filing.
- Assess the cash runway against actual operating burn and the timing and cost of planned trials; the stated 12-month runway excludes starting CLBS14 Phase 3 without additional funding.
- Separate recurring operating performance from the one-time $10.9 million tax benefit when evaluating the nine-month net loss.
- Review share-count growth, remaining ATM capacity, warrants, and potential dilution from future capital raises or warrant exercises.
- Check subsequent disclosures on HONEDRA enrollment, CLBS16 and CLBS119 trial progress, COVID-19 impacts, financing, and appointment of a permanent CFO.